Results 241 to 250 of about 406,045 (339)
Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report. [PDF]
Strijdhorst A +4 more
europepmc +1 more source
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu +18 more
wiley +1 more source
How should immune checkpoint inhibitor myocarditis be treated? [PDF]
Badaan S +4 more
europepmc +1 more source
Identifying Cytokine Motif‐Containing, Immunomodulatory Bacterial Proteins in Human Gut Microbiome
By building and constructing HMM (Upper left, blue), the authors identify CMCPs in bacteria genomes and CRC related metagenomes and enriched CRC‐related CMCPs (Upper right, blue). They analyze sequence and structural similarity of hits (Lower left, green), test function with engineered EcN delivered to tumors in a mouse tumor model (Lower right, pink ...
Ziyu Wang +12 more
wiley +1 more source
Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database. [PDF]
Cao L, Wang Y, Dai P, Li X.
europepmc +1 more source
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo +14 more
wiley +1 more source
Proteostasis of immune checkpoint receptors. [PDF]
Tey PY, Urbé S, Clague MJ.
europepmc +1 more source
Macrophage Extracellular Traps in Immunity and Cancer
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li +5 more
wiley +1 more source
Rituximab for the treatment of immune checkpoint inhibitor-induced glomerulonephritis. [PDF]
Alasadi Y +9 more
europepmc +1 more source

